NRG receives award to develop therapies for Parkinson’s and MND
In vitro, NRG’s investigational therapies were found to offer protection to mitochondria and avert brain cell death.
Central Nervous System
Latest in
Central Nervous System
AbbVie files NDA with US FDA for Parkinson’s disease therapy
In a Phase III trial, ABBV-951 offered statistically significant improvement in ‘On’ time without troublesome dyskinesia.
Advancements in GA pipeline brings first wave of therapies closer to patients
Recent advancements in late-stage therapies for geographic atrophy have raised hopes of ushering in its first wave of therapies.
By
Pfizer to acquire Biohaven Pharmaceutical for $11.6bn in cash
According to the deal, Pfizer will acquire CGRP programmes of Biohaven, including rimegepant, zavegepant and five pre-clinical assets.
EC approves Horizon’s Uplizna for neuromyelitis optica spectrum disorder
The latest approval is based on findings from the Phase II/III N-MOmemtum clinical trial carried out in 25 countries.
AAN 2022 highlights: complement inhibitors and pipeline assessment in neurology
Data were presented for several complement-targeting therapeutics at the American Academy of Neurology (AAN) 2022 Annual Meeting.
By
Lysogene and Yeda enter gene therapy licencing deal
Lysogene will oversee the preclinical, clinical development, production, regulatory works and marketing of the drug.
Amylyx AdCom: panelists narrowly vote against FDA approval in ALS despite strong patient advocacy
Some FDA panelists cited concerns with the ALS trial design, while others pointed to positive data and the high unmet…
By